medigraphic.com
ISSN 0188-2198 (Impreso)

2000, Número 2

<< Anterior Siguiente >>

Rev Mex Cardiol 2000; 11 (2)


Tratamiento de la insuficiencia cardiaca crónica

Villalpando GJ, Alcocer DBL, Campos FE, Cardona MEG, Llamas EG, Lozano SH, Necoechea AJC, Rivera CJ

Idioma: Español
Referencias bibliográficas: 33
Paginas: 239-253
Archivo PDF: 153.91 Kb.


FRAGMENTO

INTRODUCCIÓN


El tratamiento moderno de la insuficiencia cardiaca (IC) no puede limitarse al alivio de los síntomas. Los procesos que contribuyen a la disfunción del ventrículo izquierdo pueden progresar en forma independiente al desarrollo de los síntomas (Figura 1). El tratamiento instituido para prevenir o retrasar la progresión de la disfunción ventricular izquierda puede, por lo tanto, ser diferente del requerido para aliviar los síntomas o mejorar la calidad de vida del paciente. En virtud de que los síntomas de IC sólo guardan una ligera relación con la severidad de la disfunción ventricular izquierda, la evaluación del riesgo del paciente y la elección de la terapéutica más adecuada requiere del conocimiento de los mecanismos tanto de la disfunción del ventrículo izquierdo como de la constelación de síntomas que constituyen la IC. aunque la disfunción en sí misma está estrechamente ligada a la mortalidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cohn JN. The management of chronic heart failure. N Engl J Med 1996; 335: 490-497.

  2. Uretsky BF, Young JB, Shahidi FE et al. Randomized study assessing the effect of digoxin witdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22: 955-962.

  3. Packer M, Gheorghiade M, Young JB et al: On behalf of the RADIANCE Study: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.

  4. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. (Committe on evaluation and management of heart failuer) J Am Coll Cardiol 1995; 26: 1376-1398.

  5. SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricle ejection fractions. N Engl J Med 1992; 327: 685-691.

  6. 5ª. SOLVD Investigators . Effects of enalapril on survival in patients with reduced left ventricular fractions . and congestive heart failure. N Engl J Med 1991; 325: 293-305.

  7. Pfeffer MA, Braunwald E, Moyé, et al: On behalf of the SAVE Investigators. Effects of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.

  8. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after myocardial infarction. Curr Opin Cardiol 1997;12:407-417.

  9. ISIS-IV: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,000 patients with suspected acute myocardial infarction (Fourth International Study of Infarct Survival) Lancet 1995; 345: 669-685.

  10. Cohn JN, Johnson G, Ziesche S et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFT-II). N Engl J Med 1991; 325: 303-310.

  11. Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 31: 1429-1435.

  12. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.

  13. Cohn JN, Archibald DG, Ziesche S et al: Effects of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT-I). N Engl J Med 1986;314:1547-1552.

  14. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.

  15. Packer M, O’Connor CM, Ghali JK, et al: For the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE)) Effects of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.

  16. Waagstein F, Hjalmarson A, Varnauskas E. Effect of chronic beta-adrenergic receptors blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.

  17. Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in dilated cardiomyopathy (MDC)) Trial Study Group. Lancet 1993; 342: 1441-1446.

  18. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.

  19. Randomized trial of low-dose amiodarone in severe congestive heart failure. GESICA Trial. Lancet 1994;344:493-498.

  20. Wenger NK. Assessment of quality of life in clinical of cardiovascular therapies. Le Jacq Publ Inc, 1984

  21. Guyan GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993; 22 (Suppl A): 185ª-191ª.

  22. The MDPIT Research Group. Multicenter Diltiazem post infarction group . N Engl J Med 1988; 319: 385-392.

  23. The CAST Investigators. Cardiac Arrythmia suppression trial. N Engl J Med 1989; 321: 406-412.

  24. The German and Austrian xamoterol study group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988; 1: 489-493.

  25. Packer M, Carver JR, Rodeheffer RJ, et al: Prospective Randomized Milrinone Survival Evaluation Trial. N Engl J Med 1991; 325: 1468-1475.

  26. Feldman AM, Bristow MR, Parmley WW, et al: Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329: 149.155.

  27. Goldourt U, Behar S, Reicher-Reiss H, et al: Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israeli Nifedipine Trial II. Arch Intern Med 1993; 153: 345-353.

  28. Cohn JN, Ziesche S, Smith R, et al: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT-III. Circulation 1997; 96: 856-863.

  29. Packer M, Bristow MR, Cohn JN, et al: US Carvedilol Heart Failure Study. The effect of carvedilolon morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.

  30. Pitt b, Segal R, Martínez FA, et al: Randomized trialof Losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in The Elderly study :ELIT). Lancet 1997; 349: 747-752.

  31. Yusuf S, Maggiori AP, Held P, Rouleau JL. Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function , clinical deterioration and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction. (RESOLVD) Circulation 1997; 96 (Suppl 1): I-452.

  32. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study (CIBIS II). A randomized trial. Lancet 1999; 353: 9-13.

  33. RALES. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.




2020     |     www.medigraphic.com